Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-specific iPSC-derived CD8+ cytotoxic T lymphocytes
- Development stage
- Preclinical
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA-specific iPSC-derived CD8+ cytotoxic T lymphocytes (CTLs) are an investigational, rejuvenated allogeneic cell therapy being developed for the treatment of multiple myeloma. Developed by researchers at the Dana-Farber Cancer Institute, Harvard University, and Kyoto University, this therapy is generated by epigenetically reprogramming precursor exhausted B-cell maturation antigen (BCMA)-specific CD8+ memory CTLs into induced pluripotent stem cells (iPSCs). These iPSCs are then differentiated into hematopoietic progenitor cells and subsequently re-differentiated into highly functional, rejuvenated CD8αβ+ memory T cells. This approach aims to overcome the limitations of T-cell exhaustion and senescence associated with conventional autologous CAR-T cell therapies, providing a renewable source of highly proliferative, polyfunctional, and antigen-specific memory CTLs that target BCMA-expressing multiple myeloma cells in an HLA-A2-restricted manner.
- Other names
- BCMA-specific iPSC-derived CD8+ CTLsBCMA-specific iPSC-derived CD8+ T cellsBCMA-specific iPSC-derived CD8αβ+ memory T cellsBCMA-specific iPSC-derived CD8αβ+ T cellsrejuvenated BCMA-specific CD8+ CTLsrejuvenated BCMA-specific CD8+ cytotoxic T lymphocytes
02
Targets
BCMA (B-cell maturation antigen)CD8A (T-cell surface glycoprotein CD8 alpha chain)LAT (Linker for activation of T cells)LCK (Proto-oncogene tyrosine-protein kinase Lck)
Beyond the preview
Go deeper on BCMA-specific iPSC-derived CD8+ cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-specific iPSC-derived CD8+ cytotoxic T lymphocytes.